Description: Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding �1.2 billion in 2012. Ipsen�s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In 2012, R&D expenditure totaled close to �250 million, representing more than 20% of Group sales. The Group has total worldwide staff of close to 4,900 employees.
Home Page: www.ipsen.com
65 Quai Georges Gorse
Boulogne-Billancourt,
92100
France
Phone:
33 1 58 33 50 00
Officers
| Name | Title |
|---|---|
| Mr. David Loew | MD, CEO & Director |
| Mr. Aymeric Le Chatelier | Exec. VP & Group CFO |
| Dr. Aidan Murphy Ph.D. | Exec. VP of Technical Operations |
| Mr. Craig Marks | Vice-Pres of Investor Relations |
| Mr. Francois Garnier | Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer |
| Ms. Gwenan White | Exec. VP of Communications & Public Affairs |
| Mr. Regis Mulot | Exec. VP & Chief HR Officer |
| Mr. Stephan Gagne | Head of New Tokyo Office |
| Ms. Dominique Bery | Head of Nordics & Baltics |
| Dr. Yan Moore M.D. | Sr. VP & Head of Oncology Therapeutic Area |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 11.534 |
|---|---|
| Trailing PE: | 11.2277 |
| Price-to-Book MRQ: | 2.7317 |
| Price-to-Sales TTM: | 2.7217 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4500 |